Drug Trial Radar · NCT03709706
Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
Last checked: Nov 20, 2026Latest source record: Feb 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
34
Actual
Start
Dec 31, 2018
Primary completion
Jun 27, 2022
Study completion Nov 4, 2022
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Oct 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will evaluate safety and tolerability of letetresgene autoleucel (GSK3377794) with or without pembrolizumab in participants with non-small cell lung cancer.
Conditions
- Neoplasms
Interventions
Lete-celDrug
lete-cel will be administered to eligible participants.
PembrolizumabDrug
Pembrolizumab will be administered to eligible participants.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to approximately 10 months
- Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESI)Time frame: Up to approximately 10 months
- Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events Based on Maximum Severity GradesTime frame: Up to approximately 10 months
- Number of Participants With AEs Leading to Dose DelaysTime frame: Up to approximately 10 months
- Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator AssessmentTime frame: Up to approximately 10 months
Locations
31 sites in 5 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Duarte, California
GSK Investigational Site
La Jolla, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
Stanford, California
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Hollywood, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Iowa City, Iowa
GSK Investigational Site
Lexington, Kentucky
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
New York, New York
GSK Investigational Site
Durham, North Carolina
GSK Investigational Site
Columbus, Ohio
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Nashville, Tennessee
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Salt Lake City, Utah
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Amsterdam, Netherlands
GSK Investigational Site
Groningen, Netherlands
GSK Investigational Site
Rotterdam, Netherlands
GSK Investigational Site
Utrecht, Netherlands
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
London, United Kingdom
GSK Investigational Site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.